Does lipoprotein(a) carry oxidized phospholipids that drive vascular inflammation and risk even when hs-CRP is low?

Lipoprotein(a) [Lp(a)] is established as the primary carrier of pro-inflammatory oxidized phospholipids (OxPL) in human circulation. This relationship creates a unique pathway for cardiovascular risk that operates independently of traditional markers like LDL-cholesterol and systemic inflammation.

Clinical effectiveness and risk

Extensive cohort studies and meta-analyses, including data from over 560,000 participants, confirm that elevated Lp(a) remains a robust predictor of major adverse cardiovascular events (MACE) even when high-sensitivity C-reactive protein (hs-CRP) is low (<2 mg/L).

• Persistent Risk: In patients with low systemic inflammation, elevated Lp(a) still carries a significant hazard ratio for MACE (HR 1.26), indicating that the absence of a systemic inflammatory response does not mitigate the risk posed by Lp(a).
• Independent Burden: Unlike hs-CRP, which reflects systemic IL-6 signaling, Lp(a) confers risk through its unique pro-thrombotic properties and its role as a concentrated delivery vehicle for bioactive lipids.

Mechanistic explanations

The pro-inflammatory drive of Lp(a) is fundamentally linked to its carriage of OxPL, which are covalently bound to the apolipoprotein(a) moiety.

• Molecular Sequestration: OxPL attach specifically to the Kringle IV type 10 (KIV-10) domain of apo(a), particularly at residues His31 and His33. This sequestration protects OxPL from degradation, allowing them to reach the vessel wall in high concentrations.
• Vascular Inflammation: Once in the subendothelial space, OxPL-Lp(a) complexes act as damage-associated molecular patterns (DAMPs). They activate Toll-like receptor 4 (TLR4) and the NLRP3 inflammasome in endothelial cells and macrophages.
• Local vs. Systemic: This process triggers "smoldering" local vascular inflammation, characterized by the upregulation of adhesion molecules (ICAM-1, VCAM-1) and increased monocyte trafficking, which may not be reflected in systemic hs-CRP levels.

Bottom line

Lp(a) represents a critical source of residual inflammatory risk that is often "invisible" to standard hs-CRP testing. Its ability to drive localized vascular wall inflammation through the delivery of oxidized phospholipids necessitates its evaluation as a distinct risk factor, particularly in older patients where managing long-term atherosclerotic progression is paramount.